Symbols / KPRX $2.10 +0.48%
KPRX Chart
About
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.72M |
| Enterprise Value | -11.27M | Income | -8.54M | Sales | — |
| Book/sh | 6.53 | Cash/sh | 5.28 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -0.94 | PEG | — |
| P/S | inf | P/B | 0.32 | P/C | — |
| EV/EBITDA | 1.21 | EV/Sales | — | Quick Ratio | 8.54 |
| Current Ratio | 8.79 | Debt/Eq | 1.80 | LT Debt/Eq | — |
| EPS (ttm) | -2.20 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-07 06:00 | ROA | -17.07% |
| ROE | -32.58% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.68M |
| Shs Float | 3.53M | Short Float | 0.23% | Short Ratio | 0.11 |
| Short Interest | — | 52W High | 4.18 | 52W Low | 1.76 |
| Beta | -0.80 | Avg Volume | 46.74K | Volume | 11.84K |
| Target Price | $12.00 | Recom | None | Prev Close | $2.09 |
| Price | $2.10 | Change | 0.48% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$12.00
Mean price target
2. Current target
$2.10
Latest analyst target
3. DCF / Fair value
$-32.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.10
Low
$12.00
High
$12.00
Mean
$12.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-23 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-20 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-02-09 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-06 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-08-24 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-14 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-09 | main | Maxim Group | Buy → Buy | $2 |
| 2023-05-12 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-24 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2023-02-09 | up | Maxim Group | Hold → Buy | $12 |
| 2023-02-08 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2023-02-08 | reit | Ladenburg Thalmann | — → Buy | $119 |
- Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes - Stock Titan Fri, 06 Mar 2026 19
- KPRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Sun, 15 Mar 2026 05
- Kiora's Oppenheimer healthcare talk will stream live, replay for 90 days - Stock Titan hu, 19 Feb 2026 08
- Kiora Pharmaceuticals inks potential $110 million deal with Senju - Investing.com ue, 03 Jun 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Mon, 12 Feb 2024 02
- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31% - Yahoo Finance ue, 11 Jun 2024 07
- Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan ue, 27 Jan 2026 08
- Karyopharm Therapeutics (KPRX): Tiny Cancer Stock, Massive Drama – Is It Worth Your Money? - AD HOC NEWS Sat, 07 Feb 2026 08
- KPRX Forecast — Price Prediction for 2026. Should I Buy KPRX? - Intellectia AI Sat, 31 May 2025 12
- Kiora Pharmaceuticals (KPRX) - Zacks Investment Research ue, 09 Nov 2021 11
- KPRX Forecast — Price Target — Prediction for 2027 - TradingView hu, 15 Sep 2022 12
- Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis - MarketBeat ue, 16 Nov 2021 10
- We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance Fri, 15 Nov 2024 08
- Karyopharm Therapeutics: Speculative Biotech Stock Caught Between Deep Losses And Quiet Hope - AD HOC NEWS Sun, 18 Jan 2026 08
- Why Is Revelation Biosciences (REVB) Stock Down 62% Today? - InvestorPlace hu, 01 Feb 2024 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 16733 | — | — | Stock Award(Grant) at price 0.00 per share. | STREM BRIAN M. | Chief Executive Officer | — | 2026-03-06 00:00:00 | D |
| 1 | 6533 | — | — | Stock Award(Grant) at price 0.00 per share. | DANIELS ERIC JOSEPH | Officer | — | 2026-03-06 00:00:00 | D |
| 2 | 6533 | — | — | Stock Award(Grant) at price 0.00 per share. | TOSCA MELISSA | Chief Financial Officer | — | 2026-03-06 00:00:00 | D |
| 3 | 15941 | — | — | Stock Award(Grant) at price 0.00 per share. | STREM BRIAN M. | Chief Executive Officer | — | 2025-04-01 00:00:00 | D |
| 4 | 7772 | — | — | Stock Award(Grant) at price 0.00 per share. | DANIELS ERIC JOSEPH | Officer | — | 2025-04-01 00:00:00 | D |
| 5 | 7772 | — | — | Stock Award(Grant) at price 0.00 per share. | TOSCA MELISSA | Chief Financial Officer | — | 2025-04-01 00:00:00 | D |
| 6 | 1250 | 4600 | — | Purchase at price 3.68 per share. | STENGONE CARMINE N | Director | — | 2024-09-11 00:00:00 | D |
| 7 | 3000 | 10800 | — | Purchase at price 3.60 per share. | SHAPIRO ARON | Director | — | 2024-09-10 00:00:00 | I |
| 8 | 5000 | 19800 | — | Purchase at price 3.96 per share. | TYLE PRAVEEN | Director | — | 2024-08-19 00:00:00 | D |
| 9 | 1250 | 4825 | — | Purchase at price 3.86 per share. | WALTERS-HOFFERT LISA | Director | — | 2024-08-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -427.34K | -824.27K | -57.10K | -45.31K |
| TaxRateForCalcs | 0.36 | 0.21 | 0.03 | 0.01 |
| NormalizedEBITDA | 6.88M | -8.44M | -11.64M | -10.63M |
| TotalUnusualItems | -1.18M | -3.93M | -2.00M | -3.28M |
| TotalUnusualItemsExcludingGoodwill | -1.18M | -3.93M | -2.00M | -3.28M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 3.59M | -12.51M | -13.58M | -13.77M |
| ReconciledDepreciation | 19.20K | 51.80K | 41.61K | 45.30K |
| EBITDA | 5.70M | -12.36M | -13.65M | -13.91M |
| EBIT | 5.68M | -12.41M | -13.69M | -13.96M |
| NetInterestIncome | 1.23M | 162.86K | 48.29K | -5.71K |
| InterestExpense | 21.45K | 11.13K | 8.60K | 6.85K |
| InterestIncome | 1.25M | 173.99K | 56.89K | 1.14K |
| NormalizedIncome | 4.35M | -9.41M | -11.64M | -10.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 3.59M | -12.51M | -13.58M | -13.77M |
| TotalExpenses | 10.42M | 8.69M | 11.73M | 10.67M |
| TotalOperatingIncomeAsReported | 4.51M | -12.59M | -12.31M | -14.24M |
| DilutedAverageShares | 4.13M | 538.01K | 81.37K | 26.79K |
| BasicAverageShares | 3.87M | 538.01K | 81.37K | 26.79K |
| DilutedEPS | 0.87 | -24.25 | -166.95 | -514.08 |
| BasicEPS | 0.93 | -24.25 | -166.95 | -514.08 |
| DilutedNIAvailtoComStockholders | 3.59M | -13.04M | -13.58M | -13.77M |
| NetIncomeCommonStockholders | 3.59M | -13.04M | -13.58M | -13.77M |
| OtherunderPreferredStockDividend | 0.00 | 530.99K | 0.00 | |
| NetIncome | 3.59M | -12.51M | -13.58M | -13.77M |
| NetIncomeIncludingNoncontrollingInterests | 3.59M | -12.51M | -13.58M | -13.77M |
| NetIncomeContinuousOperations | 3.59M | -12.51M | -13.58M | -13.77M |
| TaxProvision | 2.07M | 90.32K | -113.01K | -192.60K |
| PretaxIncome | 5.66M | -12.42M | -13.70M | -13.96M |
| OtherIncomeExpense | -1.15M | -3.90M | -2.02M | -3.28M |
| OtherNonOperatingIncomeExpenses | 26.07K | 28.84K | -14.50K | |
| SpecialIncomeCharges | -1.18M | -3.93M | -578.39K | -3.28M |
| GainOnSaleOfPPE | -3.86K | -28.38K | 4.21K | 0.00 |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | -278.19K | |||
| WriteOff | 2.01M | 1.90M | 0.00 | |
| ImpairmentOfCapitalAssets | 104.17K | 0.00 | 4.04M | |
| RestructuringAndMergernAcquisition | -937.47K | 1.99M | 582.61K | -475.96K |
| GainOnSaleOfSecurity | -1.43M | |||
| NetNonOperatingInterestIncomeExpense | 1.23M | 162.86K | 48.29K | -5.71K |
| InterestExpenseNonOperating | 21.45K | 11.13K | 8.60K | 6.85K |
| InterestIncomeNonOperating | 1.25M | 173.99K | 56.89K | 1.14K |
| OperatingIncome | 5.58M | -8.69M | -11.73M | -10.67M |
| OperatingExpense | 10.42M | 8.69M | 11.73M | 10.67M |
| OtherOperatingExpenses | -20.00K | |||
| ResearchAndDevelopment | 4.90M | 4.03M | 3.45M | 5.35M |
| SellingGeneralAndAdministration | 5.54M | 4.66M | 8.28M | 5.32M |
| GeneralAndAdministrativeExpense | 5.54M | 4.66M | 8.28M | 5.32M |
| OtherGandA | 5.54M | 4.66M | 8.28M | 5.32M |
| TotalRevenue | 16.00M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 16.00M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.00M | 856.18K | 199.61K | 35.18K |
| ShareIssued | 3.00M | 856.18K | 199.61K | 35.18K |
| TotalDebt | 57.17K | 106.89K | 105.78K | 209.41K |
| TangibleBookValue | 19.07M | -2.70M | 664.44K | 3.81M |
| InvestedCapital | 25.76M | 6.11M | 11.41M | 14.58M |
| WorkingCapital | 23.70M | 3.10M | 4.41M | 7.38M |
| NetTangibleAssets | 19.07M | -2.70M | 664.44K | 3.81M |
| CapitalLeaseObligations | 57.17K | 106.89K | 105.78K | 209.41K |
| CommonStockEquity | 25.76M | 6.11M | 11.41M | 14.58M |
| PreferredStockEquity | 4.00 | 4.00 | ||
| TotalCapitalization | 25.76M | 6.11M | 11.41M | 14.58M |
| TotalEquityGrossMinorityInterest | 25.76M | 6.11M | 11.41M | 14.58M |
| StockholdersEquity | 25.76M | 6.11M | 11.41M | 14.58M |
| GainsLossesNotAffectingRetainedEarnings | -282.16K | -182.80K | -182.74K | -86.43K |
| OtherEquityAdjustments | -282.16K | -182.80K | -182.74K | -86.43K |
| RetainedEarnings | -143.38M | -146.98M | -134.46M | -120.88M |
| AdditionalPaidInCapital | 169.16M | 153.19M | 146.04M | 135.54M |
| CapitalStock | 267.68K | 77.08K | 17.99K | 3.17K |
| CommonStock | 267.68K | 77.08K | 17.99K | 3.17K |
| PreferredStock | 4.00 | 4.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 10.72M | 7.60M | 7.27M | 5.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.72M | 5.97M | 4.00M | 3.94M |
| OtherNonCurrentLiabilities | 4.19M | 5.13M | 3.31M | 3.05M |
| NonCurrentDeferredLiabilities | 490.69K | 779.44K | 689.12K | 802.13K |
| NonCurrentDeferredTaxesLiabilities | 490.69K | 779.44K | 689.12K | 802.13K |
| LongTermDebtAndCapitalLeaseObligation | 33.81K | 59.82K | 0.00 | 90.57K |
| LongTermCapitalLeaseObligation | 33.81K | 59.82K | 0.00 | 90.57K |
| CurrentLiabilities | 6.01M | 1.63M | 3.27M | 1.61M |
| OtherCurrentLiabilities | 322.38K | |||
| CurrentDebtAndCapitalLeaseObligation | 23.36K | 47.07K | 105.78K | 118.85K |
| CurrentCapitalLeaseObligation | 23.36K | 47.07K | 105.78K | 118.85K |
| PayablesAndAccruedExpenses | 5.99M | 1.59M | 2.84M | 1.49M |
| CurrentAccruedExpenses | 3.24M | 1.38M | 1.84M | 1.33M |
| Payables | 2.74M | 206.26K | 1.01M | 160.62K |
| TotalTaxPayable | 2.33M | 0.00 | ||
| IncomeTaxPayable | 2.33M | 0.00 | ||
| AccountsPayable | 415.59K | 206.26K | 1.01M | 160.62K |
| TotalAssets | 36.48M | 13.71M | 18.68M | 20.13M |
| TotalNonCurrentAssets | 6.78M | 8.97M | 11.00M | 11.14M |
| OtherNonCurrentAssets | 28.97K | 45.03K | 82.26K | 87.96K |
| GoodwillAndOtherIntangibleAssets | 6.69M | 8.81M | 10.74M | 10.77M |
| OtherIntangibleAssets | 6.69M | 8.81M | 10.74M | 10.77M |
| Goodwill | 0.00 | |||
| NetPPE | 62.40K | 114.95K | 172.17K | 283.41K |
| AccumulatedDepreciation | -1.02K | -6.29K | -117.32K | -113.13K |
| GrossPPE | 63.43K | 121.24K | 289.49K | 396.54K |
| Leases | 0.00 | 22.57K | 22.57K | |
| OtherProperties | 57.17K | 118.72K | 205.39K | 297.81K |
| MachineryFurnitureEquipment | 6.26K | 2.52K | 61.53K | 76.16K |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 29.71M | 4.74M | 7.68M | 8.99M |
| OtherCurrentAssets | 2.04M | 233.38K | 343.07K | 606.52K |
| PrepaidAssets | 606.52K | |||
| Receivables | 871.44K | 2.05M | 1.37M | 529.56K |
| OtherReceivables | 601.20K | 529.56K | ||
| TaxesReceivable | 270.25K | 2.05M | 1.37M | 529.56K |
| CashCashEquivalentsAndShortTermInvestments | 26.79M | 2.45M | 5.96M | 7.85M |
| OtherShortTermInvestments | 23.00M | 0.00 | ||
| CashAndCashEquivalents | 3.79M | 2.45M | 5.96M | 7.85M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 8.55M | -9.56M | -10.43M | -10.74M |
| RepurchaseOfCapitalStock | 0.00 | -15.63K | 0.00 | |
| RepaymentOfDebt | 0.00 | -212.28K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 15.00M | 6.97M | 5.38M | 17.75M |
| CapitalExpenditure | -6.26K | -63.87K | ||
| EndCashPosition | 3.80M | 2.46M | 6.01M | 7.90M |
| BeginningCashPosition | 2.46M | 6.01M | 7.90M | 1.23M |
| EffectOfExchangeRateChanges | -57.23K | 36.02K | -85.04K | -81.50K |
| ChangesInCash | 1.39M | -3.59M | -1.80M | 6.75M |
| FinancingCashFlow | 15.50M | 5.97M | 8.62M | 17.58M |
| CashFlowFromContinuingFinancingActivities | 15.50M | 5.97M | 8.62M | 17.58M |
| NetOtherFinancingCharges | -1.19M | -1.31M | -1.00M | |
| ProceedsFromStockOptionExercised | 1.69M | 307.08K | 3.26M | 50.00K |
| NetCommonStockIssuance | 15.00M | 6.97M | 5.36M | 17.75M |
| CommonStockPayments | 0.00 | -15.63K | 0.00 | |
| CommonStockIssuance | 15.00M | 6.97M | 5.38M | 17.75M |
| NetIssuancePaymentsOfDebt | 0.00 | -212.28K | ||
| NetLongTermDebtIssuance | 0.00 | -212.28K | ||
| LongTermDebtPayments | 0.00 | -212.28K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -22.66M | 0.00 | 6.38K | -157.02K |
| CashFlowFromContinuingInvestingActivities | -22.66M | 0.00 | 6.38K | -157.02K |
| NetInvestmentPurchaseAndSale | -22.66M | 0.00 | ||
| SaleOfInvestment | 12.98M | 0.00 | ||
| PurchaseOfInvestment | -35.63M | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | -93.16K | ||
| PurchaseOfBusiness | 0.00 | -93.16K | ||
| NetPPEPurchaseAndSale | -6.26K | 0.00 | 6.38K | -63.87K |
| SaleOfPPE | 0.00 | 6.38K | 0.00 | |
| PurchaseOfPPE | -6.26K | 0.00 | 0.00 | -63.87K |
| OperatingCashFlow | 8.56M | -9.56M | -10.43M | -10.68M |
| CashFlowFromContinuingOperatingActivities | 8.56M | -9.56M | -10.43M | -10.68M |
| ChangeInWorkingCapital | 3.67M | -1.82M | 668.51K | -1.04M |
| ChangeInOtherCurrentLiabilities | -46.50K | 584.00 | -103.63K | -181.98K |
| ChangeInOtherCurrentAssets | 15.23K | -7.58K | -22.46K | 14.11K |
| ChangeInPayablesAndAccruedExpense | 4.49M | -1.27M | 1.39M | -269.78K |
| ChangeInAccruedExpense | 4.26M | -459.71K | 609.72K | 40.88K |
| ChangeInPayable | 226.12K | -808.02K | 782.46K | -310.67K |
| ChangeInAccountPayable | 226.12K | -808.02K | 782.46K | -310.67K |
| ChangeInPrepaidAssets | -1.82M | 885.00 | 275.16K | -156.95K |
| ChangeInReceivables | 1.03M | -548.11K | -872.74K | -441.20K |
| OtherNonCashItems | -916.78K | 2.00M | 675.02K | -323.70K |
| StockBasedCompensation | 656.59K | 754.94K | 462.45K | 842.48K |
| UnrealizedGainLossOnInvestmentSecurities | 119.00 | 0.00 | ||
| AssetImpairmentCharge | 2.11M | 1.90M | 0.00 | 4.04M |
| AmortizationOfSecurities | -283.47K | 0.00 | ||
| DeferredTax | -288.75K | 90.32K | -113.01K | -192.60K |
| DeferredIncomeTax | -288.75K | 90.32K | -113.01K | -192.60K |
| DepreciationAmortizationDepletion | 19.20K | 51.80K | 41.61K | 45.30K |
| DepreciationAndAmortization | 19.20K | 51.80K | 41.61K | 45.30K |
| AmortizationCashFlow | 19.20K | 51.80K | 25.00K | |
| AmortizationOfIntangibles | 19.20K | 51.80K | 25.00K | |
| Depreciation | 20.30K | |||
| OperatingGainsLosses | -759.00 | -25.50K | 1.42M | -278.19K |
| GainLossOnInvestmentSecurities | -4.52K | 1.43M | ||
| GainLossOnSaleOfPPE | 3.76K | 28.38K | -4.21K | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | -53.88K | 0.00 | |
| NetIncomeFromContinuingOperations | 3.59M | -12.51M | -13.58M | -13.77M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KPRX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|